ArticleEndocrine connections2023
Treatment burden, adherence, and quality of life in children with daily GH treatment in France.
Article in Endocrine connections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The burden of illness in Prader-Willi syndrome: a systematic literature review.Orphanet journal of rare diseases · 2025Pooled it
- A comprehensive systematic review of health-related quality of life measures in short stature paediatric patients.Endocrine · 2024Pooled it
- Somapacitan Is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: A Randomized Controlled Phase 3 Study.Hormone research in paediatrics · 2026Trial
- Somapacitan in Children Born SGA: 52-Week Efficacy, Safety, and IGF-I Response Results From the Phase 2 REAL5 Study.The Journal of clinical endocrinology and metabolism · 2025Trial
- Association of Growth Hormone Adherence and Growth Outcomes in Paediatric Patients: Results From a Clinical Registry.Clinical endocrinology · 2026Article
- Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency.Journal of the Endocrine Society · 2026Article
- Narrative medicine approach for assessing the emotional experience of children and adolescents treated with daily rhGH and their caregivers.Frontiers in endocrinology · 2026Article
- Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector.Journal of the Endocrine Society · 2025Article
- Stigma in differences of sex development: a scoping review.Journal of pediatric psychology · 2025Article
- Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece.Endocrine · 2025Article
- Article
- Patient Characteristics Associated With Annual Nutrition Visits in Children With Type 1 Diabetes.Pediatric diabetes · 2025Article
- Discomfort towards peers causes therapy-related stress in children and adolescents on daily rhGH therapy.Frontiers in endocrinology · 2025Observational
- Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.Advances in therapy · 2023Article
- COMPARATIVE GROWTH OUTCOMES OF LONG-ACTING AND SHORT-ACTING GROWTH HORMONE THERAPY IN PEDIATRIC PATIENTS: A 12-MONTH RETROSPECTIVE ANALYSIS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study was to describe in a real-life setting the treatment burden and adherence and quality of life (QOL) of children treated with daily injections of growth hormone and their relationship with treatment duration. Design: This non-interventional, multicenter, cross-sectional French study involved children aged 3-17 years treated with daily growth hormone injections. Methods: Based on a recent validated dyad questionnaire, the mean overall life interference total score (100 = most interference) was described, with treatment adherence and QOL, using the Quality of Life of Short Stature Youth questionnaire (100 = best). All analyses were performed according to treatment duration prior to inclusion. Results: Among the 275/277 analyzed children, 166 (60.4%) had only growth hormone deficiency (GHD). In the GHD group, the mean age was 11.7 ± 3.2 years; median treatment duration was 3.3 years (interquartile range 1.8-6.4). The mean overall life interference total score was 27.7 ± 20.7 (95% CI (24.2; 31.2)), with non-significant correlation with treatment duration (P = 0.1925). Treatment adherence was good (95.0% of children reported receiving >80% of planned injections over the last month); it slightly decreased with treatment duration (P = 0.0364). Children's overall QOL was good (81.5 ± 16.6 and 77.6 ± 18.7 according to children and parents, respectively), but subscores of the coping and treatment impact domains were <50. Similar results were observed in all patients independently of the condition requiring treatment. Conclusions: This real-life French cohort confirms the treatment burden of daily growth hormone injections, as previously reported in an interventional study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.